Melanoma is the leading cause of
cancer-related death in women aged 25–30[1]

Melanoma, the most deadly of skin cancers, has an increasing worldwide incidence with more than 96,000 people diagnosed annually in the US and 16,200 in the UK.[2,3]

Currently, disease staging and risk of spread (metastasis) is based on the microscopic appearance/depth of the original tumour according to the American Joint Committee on Cancer (AJCC) staging criteria.[4,5] In this system, melanomas classified as early (Stage I) tumours are treated by surgical excision and all patients are followed up clinically for up to 5 years post-diagnosis.[4,5] However, only 15% or fewer patients with early AJCC stage I or II melanomas will go on to develop metastases.[6] There is an urgent need for better risk stratification of melanomas to spare the remaining 85% of patients from the psychological and time burden of standard follow-up protocols and reduce unnecessary pressure on health systems.

Melanoma Skin Cancer (ICD-10 C43), European
Age-Standardised Incidence Rates, UK, 1993–2017

Melanoma Skin Cancer (ICD-10 C43), European Age-Standardised Incidence Rates, UK, 1993–2017

Adapted from Cancer Research UK.[3]
Worldwide, around 132,000 people are diagnosed with malignant melanoma every year.[7]

Our prognostic test for melanoma:
making it available to those in need

AMLo Biosciences aims to deliver our prognostic biomarker test (AMBLor®) to non-ulcerated AJCC Stage I and II cutaneous melanomas, which represent approximately 91% of all cases at initial presentation.[3]

AMLo Biosciences is registering AMBLor® in the major global territories, making our prognostic test for melanoma available to those in need.

%

AJCC Stage I & II cutaneous melanomas [3]

0%

Only 15% of Stage I & II tumours develop metastatic disease [5,6]

Risk of disease progression is currently determined based on pathological features of the surgically removed melanoma and current standard of care is that all patients are treated as if they are at equal risk of the disease spreading. Given that the vast majority of Stage I or II tumours will not go on to develop metastatic disease,[5,6] there is a need to identify these patients at low risk of progression for whom a less intensive follow-up regime than current standard of care is appropriate.

By identifying those at low risk of progression at an early stage, we aim to reduce the physiological and psychological burden and increase reassurance for those individuals.

We put patients at the heart of everything we do

AMLo Biosciences is committed to:

  • Reducing mortality from malignant melanoma by accurately identifying the risk of metastatic disease in early-stage melanomas using our simple and cost-effective immunohistochemical test—AMBLor®
  • Providing peace of mind for patients with melanoma that are truly at low-risk of disease progression, by providing them with an accurate determination of their true risk of progression
  • Improving patient outcomes and reducing the financial burden of melanoma on global healthcare economies
Patient undergoing visual inspection with dermatoscope

Active patient involvement from the very start

AMLo Biosciences’ aim of putting patients at the centre of everything we do is not only applied to our products. We have actively encouraged involvement of melanoma patients, their carers and their families, as well as patient organisations such as Melanoma Focus and the British Skin Foundation, in the development of our company.

In the past few years, projects associated with the development of AMBLor® have attracted nearly £2 million in research funding and £2.4 million in equity funding.

All of our projects have been actively developed with patient involvement, with our latest studies having at least three patients sitting on the steering committee of each project.

We actively disseminate research findings through our associated melanoma patient support group (over 50 members at South Tees Hospitals, United Kingdom). In return, we are able to receive feedback on our work and future project planning from the public, who ultimately will benefit most from our discoveries.

References

  1. National Council on Skin Cancer Prevention. Skin Cancer Facts & Statistics. Available at: https://skincancerprevention.org/learning/melanoma-facts-statistics/. Accessed September 2021.
  2. International Agency for Research on Cancer. Estimated number of incident cases United States of America, both sexes, all ages. Available at: https://gco.iarc.fr. Accessed September 2021.
  3. Cancer Research UK. Melanoma skin cancer statistics. Available at: https://www.cancerresearchuk.org/. Accessed September 2021.
  4. Keunga EZ, Gershenwald JE. Expert Rev Anticancer Ther. 2018;18(8):775–84.
  5. Gershenwald JE, et al. CA Cancer J Clin. 2017;67:472–92.
  6. Ellis R, et al. Br J Dermatol. 2020;182(1):156–65.
  7. World Health Organization. Radiation: Ultraviolet (UV) radiation and skin cancer, 16 October 2017. Q&A. What are the different types of skin cancer? Available at: https://www.who.int/news-room/q-a-detail/radiation-ultraviolet-(uv)-radiation-and-skin-cancer. Accessed September 2021.

Date of preparation: September 2021
Job code: 2021/AMBLor/UK/0015

AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534

Trading address: Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX

Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom

VAT # 285288950

Sign up for our newsletter